Nahla Said M. Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nahla Said M. Ibrahim has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Ashraf F. Zaher
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
3 shared publicationsHanan H. Kadry
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy Cairo University Cairo Egypt
2 shared publicationsKhaled O. Mohamed
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
2 shared publications- Hanan H. Kadry
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
1 shared publication - Khaled Omar Mohamed
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy Cairo University Cairo Egypt
1 shared publication
Latest Publications
- Open Access
- 12 February 2024
- Published by Springer Nature in Chemical Papers
- Vol. 78 (5) , 2729-2755
Review: synthesis and anticancer activity of pyrimido[4,5-b]quinolines in the last twenty years
Pyrimido[4,5-b]quinoline is a vital structural motif. The synthesis of pyrimido[4,5-b]quinolines has been a challenging topic in medicinal chemistry. A wide range of starting materials have been employed to achieve this nucleus such as quinoline derivatives and isatins. Multi-component one-pot synthestic approaches were employed either by using barbituric or thiobarbituric acid, amines and aldehydes or from 6-aminouracils, aldehydes and cyclohexanone derivatives. Recent synthetic strategies and many green chemistry techniques have improved pyrimido[4,5-b]quinolines synthesis over the last twenty years. Among the many reported biological activities of pyrimido[4,5-b]quinolines, anticancer activity attracted research attention over the past couple of decades. Many derivatives have shown promising anticancer activity on different cancer cell lines such as MCF-7, A549, K562 and others. They also demonstrated activity on different enzymes and receptors such as tyrosine kinases, tyrosyl-DNA Phosphodiesterase II and HDM2 ubiquitin ligase (E3) that promote apoptosis, repair DNA damage, and induce cell cycle arrest. This review critically examines the recent synthetic approaches employed for the synthesis of pyrimido[4,5-b]quinolines and explores their reported anticancer activities.
- 12 February 2024
- Published by Springer Nature in Chemical Papers
- Vol. 78 (5) , 2729-2755
Open AccessReview: synthesis and anticancer activity of pyrimido[4,5-b]quinolines in the last twenty years
Pyrimido[4,5-b]quinoline is a vital structural motif. The synthesis of pyrimido[4,5-b]quinolines has been a challenging topic in medicinal chemistry. A wide range of starting materials have been employed to achieve this nucleus such as quinoline derivatives and isatins. Multi-component one-pot synthestic approaches were employed either by using barbituric or thiobarbituric acid, amines and aldehydes or from 6-aminouracils, aldehydes and cyclohexanone derivatives. Recent synthetic strategies and many green chemistry techniques have improved pyrimido[4,5-b]quinolines synthesis over the last twenty years. Among the many reported biological activities of pyrimido[4,5-b]quinolines, anticancer activity attracted research attention over the past couple of decades. Many derivatives have shown promising anticancer activity on different cancer cell lines such as MCF-7, A549, K562 and others. They also demonstrated activity on different enzymes and receptors such as tyrosine kinases, tyrosyl-DNA Phosphodiesterase II and HDM2 ubiquitin ligase (E3) that promote apoptosis, repair DNA damage, and induce cell cycle arrest. This review critically examines the recent synthetic approaches employed for the synthesis of pyrimido[4,5-b]quinolines and explores their reported anticancer activities.
- 26 December 2023
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (3) , e2300513
Synthesis of novel pyrimido[4,5‐b]quinoline derivatives as dual EGFR/HER2 inhibitors as anticancer agents
A series of novel N‐aryl‐5‐aryl‐6,7,8,9‐tetrahydropyrimido[4,5‐b]quinolin‐4‐amines 4a–4l was synthesized as potential anticancer agents through Dimroth rearrangement reaction of intermediates 3a–3c. Pyrimido[4,5‐b]quinolines 4a–4l showed promising activity against the Michigan Cancer Foundation‐7 (MCF‐7) cell line, compared with lapatinib as the reference drug. Compounds 4d, 4h, 4i, and 4l demonstrated higher cytotoxic activity than lapatinib, with IC50 values of 2.67, 6.82, 4.31, and 1.62 µM, respectively. Compounds 4d, 4i, and 4l showed promising epidermal growth factor receptor (EGFR) inhibition with IC50 values of 0.065, 0.116, and 0.052 µM, respectively. These compounds were subjected to human epidermal growth factor receptor 2 (HER2) inhibition and showed IC50 values of 0.09, 0.164, and 0.055 µM, respectively. Compounds 4d, 4i, and 4l are good candidates as dual EGFR/HER2 inhibitors. The most active compound, 4l, was subjected to cell‐cycle analysis and induced cell‐cycle arrest at the S phase. Compound 4l induced apoptosis 60‐fold compared with control untreated MCF‐7 cells. 4l can inhibit cancer metastasis. It reduced MCF‐7 cell infiltration and metastasis by 45% compared with control untreated cells.
- 26 December 2023
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (3) , e2300513
Synthesis of novel pyrimido[4,5‐b]quinoline derivatives as dual EGFR/HER2 inhibitors as anticancer agents
A series of novel N‐aryl‐5‐aryl‐6,7,8,9‐tetrahydropyrimido[4,5‐b]quinolin‐4‐amines 4a–4l was synthesized as potential anticancer agents through Dimroth rearrangement reaction of intermediates 3a–3c. Pyrimido[4,5‐b]quinolines 4a–4l showed promising activity against the Michigan Cancer Foundation‐7 (MCF‐7) cell line, compared with lapatinib as the reference drug. Compounds 4d, 4h, 4i, and 4l demonstrated higher cytotoxic activity than lapatinib, with IC50 values of 2.67, 6.82, 4.31, and 1.62 µM, respectively. Compounds 4d, 4i, and 4l showed promising epidermal growth factor receptor (EGFR) inhibition with IC50 values of 0.065, 0.116, and 0.052 µM, respectively. These compounds were subjected to human epidermal growth factor receptor 2 (HER2) inhibition and showed IC50 values of 0.09, 0.164, and 0.055 µM, respectively. Compounds 4d, 4i, and 4l are good candidates as dual EGFR/HER2 inhibitors. The most active compound, 4l, was subjected to cell‐cycle analysis and induced cell‐cycle arrest at the S phase. Compound 4l induced apoptosis 60‐fold compared with control untreated MCF‐7 cells. 4l can inhibit cancer metastasis. It reduced MCF‐7 cell infiltration and metastasis by 45% compared with control untreated cells.
- 1 August 2023
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 102 (5) , 996-1013
Synthesis of novel pyrimido[4,5‐b]quinolines as potential anticancer agents and HER2 inhibitors
A series of N‐arylpyrimido[4,5‐b]quinolines 3a–e and 2‐aryl‐2,3‐dihydropyrimido[4,5‐b]quinoline‐4(1H)‐ones 5a–e was designed and synthesized as potential anticancer agents against breast cancer. Compounds 3e, 5a, 5b, 5d, and 5e showed promising activity against the MCF‐7 cell line. Among them, compound 5b was the most active with IC50 of 1.67 μM. Compound 5b promoted apoptosis and induced cell cycle arrest at S phase. 5b increased the level of pro‐apoptotic proteins p53, Bax, and caspase‐7 and inhibited the anti‐apoptotic protein Bcl‐2. Furthermore, all the synthesized compounds were docked into the crystal structure of HER2 (PBD: 3 pp0). Compounds 3e, 5a, 5b, 5d, and 5e showed good energy scores and binding modes. Finally, Compound 5b was evaluated on the HER2 assay and revealed good inhibition with IC50 of 0.073 μM.
- 1 August 2023
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 102 (5) , 996-1013
Synthesis of novel pyrimido[4,5‐b]quinolines as potential anticancer agents and HER2 inhibitors
A series of N‐arylpyrimido[4,5‐b]quinolines 3a–e and 2‐aryl‐2,3‐dihydropyrimido[4,5‐b]quinoline‐4(1H)‐ones 5a–e was designed and synthesized as potential anticancer agents against breast cancer. Compounds 3e, 5a, 5b, 5d, and 5e showed promising activity against the MCF‐7 cell line. Among them, compound 5b was the most active with IC50 of 1.67 μM. Compound 5b promoted apoptosis and induced cell cycle arrest at S phase. 5b increased the level of pro‐apoptotic proteins p53, Bax, and caspase‐7 and inhibited the anti‐apoptotic protein Bcl‐2. Furthermore, all the synthesized compounds were docked into the crystal structure of HER2 (PBD: 3 pp0). Compounds 3e, 5a, 5b, 5d, and 5e showed good energy scores and binding modes. Finally, Compound 5b was evaluated on the HER2 assay and revealed good inhibition with IC50 of 0.073 μM.